Neuroprotective Effects of Microglial Membrane-Derived Biomimetic Particles for Spinal Cord Injury

Inhibition of oxidative stress and inflammatory responses caused by secondary injury following traumatic spinal cord injury (SCI) is an attractive strategy in treating traumatic SCI. However, the efficacy of drugs is severely limited owing to the poor penetration of the blood spinal cord barrier (BSCB). Here, inspired by cell chemotaxis and related chemokines production at the lesion sites of SCI, the microglial membrane is selected to construct a drug delivery system with the ability to cross the BSCB and target the lesions. PR@MM is prepared based on the assembly of polylactic-co-glycolic acid (PLGA) and resveratrol (RSV) followed by microglial membrane (MM) coating. Compared to that of the uncoated nanoparticles, the enrichment of PR@MM at the lesion sites of SCI increases, which is beneficial to achieve lesion targeting of RSV and exert therapeutic functions. Both in vitro and in vivo experiments demonstrate that PR@MM has the ability to scavenge reactive oxygen species and anti-inflammatory effects, which ultimately promotes the recovery of locomotory function after SCI. Therefore, this microglial membrane-based drug delivery system provides a promising biomimetic nanomedicine for targeted therapy for SCI. A drug delivery system that readily penetrates the blood spinal cord barrier and targets spinal cord injury (SCI) is developed by using microglia-derived cell membranes to construct biomimetic polylactic-co-glycolic acid and resveratrol (PLGA-RSV) nanoparticles (PR@MM). In SCI, the PR@MM has the ability to scavenge reactive oxygen species and exerts anti-inflammatory effects, which ultimately promotes the recovery of locomotory function after SCI.image

Automated summary

A drug delivery system that readily penetrates the blood spinal cord barrier and targets spinal cord injury (SCI) is developed by using microglia-derived cell membranes to construct biomimetic polylactic-co-glycolic acid and resveratrol (PLGA-RSV) nanoparticles (PR@MM). In SCI, the PR@MM has the ability to scavenge reactive oxygen species and exerts anti-inflammatory effects, which ultimately promotes the recovery of locomotory function after SCI.